Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VCEL
stocks logo

VCEL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
90.76M
+20.41%
0.386
+1.58%
63.70M
+21.11%
-0.077
-66.3%
74.34M
+17.56%
0.092
-1025%
Estimates Revision
The market is revising Downward the revenue expectations for Vericel Corporation (VCEL) for FY2025, with the revenue forecasts being adjusted by -0.42% over the past three months. During the same period, the stock price has changed by 8.05%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.42%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+44.44%
In Past 3 Month
Stock Price
Go Up
up Image
+8.05%
In Past 3 Month
Wall Street analysts forecast VCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCEL is 54.20 USD with a low forecast of 48.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast VCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCEL is 54.20 USD with a low forecast of 48.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 36.790
sliders
Low
48.00
Averages
54.20
High
60.00
Current: 36.790
sliders
Low
48.00
Averages
54.20
High
60.00
Truist
Richard Newitter
Buy
maintain
$41 -> $50
2025-11-07
Reason
Truist
Richard Newitter
Price Target
$41 -> $50
2025-11-07
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on Vericel to $50 from $41 and keeps a Buy rating on the shares. The firm notes Q3 saw a $3M revenue beat as both MACI & Burn Care outperformed, and importantly MACI delivered year-over-year acceleration on the heels of ramping MACI arthro adoption. The Q3 MACI beat should help alleviate anxiety around the steep implied Q4 revenue ramp to achieve gdce, which was reiterated, Truist adds.
Truist
Buy
downgrade
$46 -> $41
2025-10-15
Reason
Truist
Price Target
$46 -> $41
2025-10-15
downgrade
Buy
Reason
Truist lowered the firm's price target on Vericel to $41 from $46 and keeps a Buy rating on the shares as part of a broader research note previewing Q3 results in MedTech. The firm expects "healthy" Q3 revenue and earnings across its coverage but also braces for "stock volatility", with new money feeling notably absent from the space, the analyst tells investors in a research note. Similar to Q2, specialist and fund positioning could be poised to drive excessive reactions on anything counter to crowded positioning, Truist states, adding that it is more inclined to be positive on "cleaner" names where there is less perceived controversy heading into the quarter.
BTIG
Buy -> Neutral
downgrade
2025-09-17
Reason
BTIG
Price Target
2025-09-17
downgrade
Buy -> Neutral
Reason
BTIG downgraded Vericel to Neutral from Buy without a price target. The stock is down 42% this year following two "softer" quarters, the analyst tells investors in a research note. BTIG's survey of MACI users suggests limited increases in both biopsy growth and conversion from the MACI Arthro launch to drive estimates higher. The firm points out that 60% of surgeons surveyed expect no change to MACI volumes despite Arthro as an option now.
Canaccord
Buy
downgrade
$61 -> $58
2025-08-01
Reason
Canaccord
Price Target
$61 -> $58
2025-08-01
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Vericel to $58 from $61 and keeps a Buy rating on the shares. The firm said they posted a solid quarter, beating bottom-line metrics but slightly missing MACI expectations while Epicel generated lower revenue than anticipated, even with the highest number of Epicel biopsies in a Q since 2023.
BTIG
Buy
downgrade
$58 -> $51
2025-07-14
Reason
BTIG
Price Target
$58 -> $51
2025-07-14
downgrade
Buy
Reason
BTIG lowered the firm's price target on Vericel to $51 from $58 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
TD Cowen
TD Cowen
Buy
downgrade
$72 -> $55
2025-05-09
Reason
TD Cowen
TD Cowen
Price Target
$72 -> $55
2025-05-09
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Vericel to $55 from $72 and keeps a Buy rating on the shares. The firm delivered Q1 revenue in line with its guidance for the quarter, despite facing some Epicel headwinds. While investors were likely looking for a Q1 beat, Vericel's ability to meet reiterated 2025 guidance should be the primary focus going forward. TD Cowen sees guidance of 20%-23% growth as achievable and expect stronger second half of 2025 contributions from Arthro and an expanding MACI sales force to be key drivers.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vericel Corp (VCEL.O) is 70.61, compared to its 5-year average forward P/E of -54.62. For a more detailed relative valuation and DCF analysis to assess Vericel Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-54.62
Current PE
70.61
Overvalued PE
586.38
Undervalued PE
-695.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
42.75
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
58.27
Undervalued EV/EBITDA
27.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
8.92
Current PS
0.00
Overvalued PS
11.58
Undervalued PS
6.26
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

VCEL News & Events

Events Timeline

(ET)
2025-11-06
07:57:36
Vericel projects FY25 revenue between $272M and $276M, aligning with consensus of $275.21M.
select
2025-11-06
07:57:11
Vericel Announces Q3 Earnings Per Share of 10 Cents, Exceeding Consensus Estimate of 1 Cent
select
2025-07-31 (ET)
2025-07-31
08:11:23
Vericel reaffirms FY25 MACI revenue growth in low 20% range
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-14Newsfilter
Vericel Scheduled to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025

  • Company Announcement: Vericel Corporation will participate in a fireside chat at the Stephens Annual Investment Conference on November 20, 2025, at 11:00 a.m. ET, with a webcast available on their Investor Relations website.

  • Company Overview: Vericel is a leader in advanced therapies for sports medicine and severe burn care, offering innovative cell therapies and specialty biologics to repair injuries and restore lives.

  • Product Portfolio: The company markets three main products in the U.S.: MACI® for knee cartilage repair, Epicel for skin replacement in burn patients, and holds rights to NexoBrid for eschar removal in burn treatment.

  • Contact Information: For investor inquiries, Eric Burns can be reached via email at ir@vcel.com or by phone at +1 (734) 418-4411.

[object Object]
Preview
4.0
10-21Yahoo Finance
Truist Reduces Price Target for Vericel Corporation (VCEL) from $46 to $41

  • Vericel Corporation Overview: Vericel Corporation (NASDAQ: VCEL) is recognized as a promising small-cap stock, with Truist recently lowering its price target from $46 to $41 while maintaining a Buy rating, anticipating healthy Q3 revenue despite potential stock volatility.

  • Product Portfolio and Market Position: The company specializes in patient-specific cellular therapies, including products like Epicel for skin replacement and MACI for tissue engineering, although some analysts suggest that certain AI stocks may present better investment opportunities with less risk.

[object Object]
Preview
6.5
09-22NASDAQ.COM
Analysts Forecast 15% Growth Potential for IJT Holdings

  • ETF Performance Analysis: The iShares S&P Small-Cap 600 Growth ETF (IJT) has an implied analyst target price of $162.93, indicating a potential upside of 14.64% from its current trading price of $142.12.

  • Notable Holdings with Upside: Key underlying holdings such as Arcus Biosciences (RCUS), Vericel Corp (VCEL), and QuinStreet, Inc. (QNST) show significant upside potential, with target prices suggesting increases of 134.79%, 74.06%, and 60.28% respectively from their recent trading prices.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vericel Corp (VCEL) stock price today?

The current price of VCEL is 36.79 USD — it has decreased -1.6 % in the last trading day.

arrow icon

What is Vericel Corp (VCEL)'s business?

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.

arrow icon

What is the price predicton of VCEL Stock?

Wall Street analysts forecast VCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCEL is 54.20 USD with a low forecast of 48.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vericel Corp (VCEL)'s revenue for the last quarter?

Vericel Corp revenue for the last quarter amounts to 67.50M USD, increased 16.58 % YoY.

arrow icon

What is Vericel Corp (VCEL)'s earnings per share (EPS) for the last quarter?

Vericel Corp. EPS for the last quarter amounts to 0.10 USD, decreased -600.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vericel Corp (VCEL)'s fundamentals?

The market is revising Downward the revenue expectations for Vericel Corporation (VCEL) for FY2025, with the revenue forecasts being adjusted by -0.42% over the past three months. During the same period, the stock price has changed by 8.05%.
arrow icon

How many employees does Vericel Corp (VCEL). have?

Vericel Corp (VCEL) has 357 emplpoyees as of December 05 2025.

arrow icon

What is Vericel Corp (VCEL) market cap?

Today VCEL has the market capitalization of 1.86B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free